View
comments
A new drug trial to treat a form of breast cancer has been hailed as 'groundbreaking'.
Pharmaceutical company AstraZeneca said Enhertu demonstrated a 72 per cent reduction in the risk of disease progression or death in women with HER2-positive metastatic breast cancer compared to a different medicine.
The results were presented in a Presidential Symposium at the European Society for Medical Oncology (ESMO) Congress 2021.
AstraZeneca said that despite initial treatment with trastuzumab and a taxane, people with HER2-positive metastatic breast cancer will often experience disease progression
The trial involving around 500 patients at multiple sites in Asia, Europe, North America, Oceania and South America found there was 'a strong trend towards improved overall survival' with Enhertu.
But it was pointed out that this analysis is 'not yet mature and is not statistically significant'.
AstraZeneca said that despite initial treatment with trastuzumab and a taxane, people with
